MKI67 and neoplasm: In an analysis of the P024 neoadjuvant endocrine trial, tumors from 228 postmenopausal ER+ stages 2 and 3 patients were analyzed for posttreatment ER status, Ki-67, grade, tumor size, nodes, and treatment response.